Role of cytokines in inflammatory bowel disease.

Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), represents a group of chronic disorders characterized by inflammation of the gastrointestinal tract, typically with a relapsing and remitting clinical course. Mucosal macrophages play an important role in the mucosal immune system, and an increase in the number of newly recruited monocytes and activated macrophages has been noted in the inflamed gut of patients with IBD. Activated macrophages are thought to be major contributors to the production of inflammatory cytokines in the gut, and imbalance of cytokines is contributing to the pathogenesis of IBD. The intestinal inflammation in IBD is controlled by a complex interplay of innate and adaptive immune mechanisms. Cytokines play a key role in IBD that determine T cell differentiation of Th1, Th2, T regulatory and newly described Th17 cells. Cytokines levels in time and space orchestrate the development, recurrence and exacerbation of the inflammatory process in IBD. Therefore, several cytokine therapies have been developed and tested for the treatment of IBD patients.

[1]  L. Denson,et al.  Activation of an IL‐6:STAT3‐dependent transcriptome in pediatric‐onset inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[2]  R. Xavier,et al.  IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. , 2008, The Journal of clinical investigation.

[3]  D. Podolsky,et al.  TNF receptor type I-dependent activation of innate responses to reduce intestinal damage-associated mortality. , 2008, Gastroenterology.

[4]  S. Brand,et al.  Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL‐22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status , 2008, Inflammatory bowel diseases.

[5]  J. O’Shea,et al.  Th17 cells: a new fate for differentiating helper T cells , 2008, Immunologic research.

[6]  A. Day,et al.  Local and systemic interleukin‐18 and interleukin‐18‐binding protein in children with inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[7]  J. Dayer,et al.  The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors , 2007, Arthritis research & therapy.

[8]  J. O’Shea,et al.  Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. , 2007, Seminars in immunology.

[9]  F. Pallone,et al.  Interleukin-21 (IL-21) controls inflammatory pathways in the gut. , 2007, Endocrine, metabolic & immune disorders drug targets.

[10]  M. Neurath,et al.  Exacerbation of ulcerative colitis after rituximab salvage therapy , 2007, Inflammatory bowel diseases.

[11]  T. Macdonald,et al.  New players in the cytokine orchestra of inflammatory bowel disease , 2007, Inflammatory bowel diseases.

[12]  A. Paradowska,et al.  The function of interleukin 17 in the pathogenesis of rheumatoid arthritis , 2007, Archivum Immunologiae et Therapiae Experimentalis.

[13]  M. Neurath,et al.  Mouse models of inflammatory bowel disease. , 2007, Advanced drug delivery reviews.

[14]  A. Levine,et al.  Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease , 2007, Gut.

[15]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[16]  F. Klebl,et al.  Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients , 2007, Inflammatory bowel diseases.

[17]  W. Strober,et al.  Cutting Edge: Regulatory T Cells Induce CD4+CD25−Foxp3− T Cells or Are Self-Induced to Become Th17 Cells in the Absence of Exogenous TGF-β , 2007, The Journal of Immunology.

[18]  D. Elliott,et al.  Immunologic and molecular mechanisms in inflammatory bowel disease. , 2007, The Surgical clinics of North America.

[19]  Tomohiro Watanabe,et al.  Induction of IL-13 Triggers TGF-β1-Dependent Tissue Fibrosis in Chronic 2,4,6-Trinitrobenzene Sulfonic Acid Colitis , 2007, The Journal of Immunology.

[20]  J. Yamamoto-Furusho.  Innovative therapeutics for inflammatory bowel disease. , 2007, World journal of gastroenterology.

[21]  J. Kolls,et al.  After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease? , 2007, International immunopharmacology.

[22]  M. Neuman.  Immune dysfunction in inflammatory bowel disease. , 2007, Translational research : the journal of laboratory and clinical medicine.

[23]  T. Giese,et al.  Interleukin-18 is increased only in a minority of patients with active Crohn’s disease , 2007, International Journal of Colorectal Disease.

[24]  M. Marinaro,et al.  Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. , 2006, Gastroenterology.

[25]  L. Fouser,et al.  Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides , 2006, The Journal of experimental medicine.

[26]  D. Latinne,et al.  New insights into the cellular immunology of the intestine in relation to the pathophysiology of inflammatory bowel diseases. , 2006, Acta gastro-enterologica Belgica.

[27]  M. Neurath,et al.  Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications , 2006, Gut.

[28]  F. Pallone,et al.  New mediators of immunity and inflammation in inflammatory bowel disease , 2006, Current opinion in gastroenterology.

[29]  S. Cerda,et al.  A new transcription factor that regulates TNF‐&agr; gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC , 2006, Inflammatory bowel diseases.

[30]  N. Brousse,et al.  Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. , 2006, Gastroenterology.

[31]  T. Mcclanahan,et al.  IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. , 2006, The Journal of clinical investigation.

[32]  Y. Sung,et al.  STAT3 and NF-κB Signal Pathway Is Required for IL-23-Mediated IL-17 Production in Spontaneous Arthritis Animal Model IL-1 Receptor Antagonist-Deficient Mice1 , 2006, The Journal of Immunology.

[33]  N. Shepherd,et al.  Basiliximab for the treatment of steroid‐resistant ulcerative colitis: further experience in moderate and severe disease , 2006, Alimentary pharmacology & therapeutics.

[34]  J. Schulzke,et al.  Randomized, Double Blind Controlled Trial of Subcutaneous Recombinant Human Interleukin-11 Versus Prednisolone in Active Crohn's Disease , 2006, The American Journal of Gastroenterology.

[35]  D. Hommes,et al.  Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease , 2006, Gut.

[36]  A. Bhan,et al.  A Case for Regulatory B Cells1 , 2006, The Journal of Immunology.

[37]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[38]  A. Takayanagi,et al.  Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. , 2005, Gastroenterology.

[39]  M. Zeitz,et al.  Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. , 2005, Gastroenterology.

[40]  T. Macdonald,et al.  Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. , 2005, Gastroenterology.

[41]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[42]  T. Giese,et al.  Expression of Interleukin‐12‐Related Cytokine Transcripts in Inflammatory Bowel Disease: Elevated Interleukin‐23p19 and Interleukin‐27p28 in Crohn's Disease But Not in Ulcerative Colitis , 2005, Inflammatory bowel diseases.

[43]  Yuka Kanno,et al.  Signaling by IL‐12 and IL‐23 and the immunoregulatory roles of STAT4 , 2004, Immunological reviews.

[44]  A. Levine,et al.  Mechanisms of Natural Tolerance in the Intestine: Implications for Inflammatory Bowel Disease , 2004, Inflammatory bowel diseases.

[45]  P. Mannon,et al.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. , 2004, The Journal of clinical investigation.

[46]  H. Ogata,et al.  Human intestinal epithelial cell‐derived interleukin (IL)‐18, along with IL‐2, IL‐7 and IL‐15, is a potent synergistic factor for the proliferation of intraepithelial lymphocytes , 2004, Clinical and experimental immunology.

[47]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[48]  K. Książek,et al.  Interleukin-17: a mediator of inflammatory responses , 2004, Cellular and Molecular Life Sciences CMLS.

[49]  P. Rutgeerts,et al.  Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models , 2004, Clinical and experimental immunology.

[50]  R. P. Thompson,et al.  Functional interactions between mucosal IL-1, IL-1ra and TGF-β1 in ulcerative colitis , 2004 .

[51]  Sarah L. Gaffen,et al.  Functional Cooperation between Interleukin-17 and Tumor Necrosis Factor-α Is Mediated by CCAAT/Enhancer-binding Protein Family Members* , 2004, Journal of Biological Chemistry.

[52]  P. Wei,et al.  Expression, Localization, and Functional Activity of TL1A, a Novel Th1-Polarizing Cytokine in Inflammatory Bowel Disease 1 , 2003, The Journal of Immunology.

[53]  Å. Danielsson,et al.  Over‐expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis , 2003, Clinical and experimental immunology.

[54]  R. Tersigni,et al.  TGF‐β1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis , 2003 .

[55]  T. Moseley,et al.  Interleukin-17 family and IL-17 receptors. , 2003, Cytokine & growth factor reviews.

[56]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[57]  A. Andoh,et al.  Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.

[58]  B. Vainer,et al.  Upregulation of Interleukin-12 and -17 in Active Inflammatory Bowel Disease , 2003, Scandinavian journal of gastroenterology.

[59]  K. Kallen.  The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. , 2002, Biochimica et biophysica acta.

[60]  C. Dinarello,et al.  The IL-1 family and inflammatory diseases. , 2002, Clinical and experimental rheumatology.

[61]  M. Korzon,et al.  TGF-beta (transforming growth factor-beta) in chronic inflammatory conditions - a new diagnostic and prognostic marker? , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[62]  S. V. van Deventer,et al.  IL-18-Binding Protein Expression by Endothelial Cells and Macrophages Is Up-Regulated During Active Crohn’s Disease1 , 2002, The Journal of Immunology.

[63]  R. Blumberg,et al.  Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. , 2002, Immunity.

[64]  S. Akira,et al.  Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. , 2001, Gastroenterology.

[65]  T. Macdonald,et al.  Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. , 2001, The Journal of clinical investigation.

[66]  W. Fridman,et al.  Analysis of interleukin-18, interleukin-1 converting enzyme (ICE) and interleukin-18-related cytokines in Crohn's disease lesions. , 2001, European cytokine network.

[67]  S. Kanazawa,et al.  VEGF, basic-FGF, and TGF-β in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation , 2001, American Journal of Gastroenterology.

[68]  S. Kanazawa,et al.  VEGF, basic-FGF, and TGF-β in Crohn’s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation , 2001 .

[69]  I. Lawrance,et al.  Inflammation Location, But Not Type, Determines the Increase in TGF-&bgr;1 and IGF-1 Expression and Collagen Deposition in IBD Intestine , 2001, Inflammatory bowel diseases.

[70]  A. Tromm,et al.  Interleukin-4 inhibits the increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease. , 2000, Hepato-gastroenterology.

[71]  Zemin Zhang,et al.  Interleukin (IL)-22, a Novel Human Cytokine That Signals through the Interferon Receptor-related Proteins CRF2–4 and IL-22R* , 2000, The Journal of Biological Chemistry.

[72]  J. Belaiche,et al.  Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission , 2000, International Journal of Colorectal Disease.

[73]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[74]  T. Kishimoto,et al.  IL-6 Is Required for the Development of Th1 Cell-Mediated Murine Colitis1 , 2000, The Journal of Immunology.

[75]  W. Fridman,et al.  Interleukin-18: biological properties and clinical implications. , 2000, European cytokine network.

[76]  Jamila Louahed,et al.  Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), a Novel Cytokine Structurally Related to IL-10 and Inducible by IL-91 , 2000, The Journal of Immunology.

[77]  H. Kiyono,et al.  Alteration of Interleukin 4 Production Results in the Inhibition of T Helper Type 2 Cell–Dominated Inflammatory Bowel Disease in T Cell Receptor α Chain–Deficient Mice , 1999, The Journal of experimental medicine.

[78]  E. Mizoguchi,et al.  The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice. , 1999, Gastroenterology.

[79]  F. Baert,et al.  Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications , 1999, International Journal of Colorectal Disease.

[80]  Seidman,et al.  Colonic explant production of IL‐1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD) , 1998, Clinical and experimental immunology.

[81]  H. Okamura,et al.  Regulation of interferon-γ production by IL-12 and IL-18 , 1998 .

[82]  C. Moskaluk,et al.  IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. , 1998, Journal of immunology.

[83]  G. Rogler,et al.  Cytokines in Inflammatory Bowel Disease , 1998, World Journal of Surgery.

[84]  M. McAlindon,et al.  Expression of interleukin 1β and interleukin 1β converting enzyme by intestinal macrophages in health and inflammatory bowel disease , 1998, Gut.

[85]  J. Reimund,et al.  Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease , 1996, Journal of Clinical Immunology.

[86]  S. Schreiber,et al.  Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. , 1995, Gastroenterology.

[87]  K. Tanikawa,et al.  Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. , 1995, Gut.

[88]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[89]  K. Rajewsky,et al.  Interleukin-10-deficient mice develop chronic enterocolitis , 1993, Cell.

[90]  S. James,et al.  The immunologic basis of inflammatory bowel disease , 1986, Journal of Clinical Immunology.

[91]  J. O’Shea,et al.  Th17 cells: a new fate for differentiating helper T cells , 2008, Immunologic research.

[92]  T. Macdonald,et al.  A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. , 2007, Gastroenterology.

[93]  R. D. Hatton,et al.  Transforming growth factor-beta induces development of the T(H)17 lineage. , 2006, Nature.

[94]  J. Stockman.  Anti-Interleukin-12 Antibody for Active Crohn's Disease , 2006 .

[95]  R. Puri,et al.  IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. , 2006, Nature medicine.

[96]  F. León,et al.  Involvement of dendritic cells in the pathogenesis of inflammatory bowel disease. , 2006, Advances in experimental medicine and biology.

[97]  R. P. Thompson,et al.  Functional interactions between mucosal IL-1, IL-ra and TGF-beta 1 in ulcerative colitis. , 2004, Inflammation research : official journal of the European Histamine Research Society ... [et al.].

[98]  R. Tersigni,et al.  TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis. , 2003, Clinical and experimental immunology.

[99]  J. Shepherd,et al.  IL-1 Receptor Antagonist-Deficient Mice , 2003 .

[100]  鈴木 飛鳥.  CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation , 2001 .

[101]  T. Tanimoto,et al.  Interleukin 18 induces a synergistic enhancement of interferon gamma production in mixed murine spleen cell-tumor cell cultures: role of endogenous interleukin 12. , 2000, Cancer detection and prevention.

[102]  Ren Dm,et al.  Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. , 2000 .

[103]  S. Targan,et al.  Role of cytokines in the pathogenesis of inflammatory bowel disease. , 2000, Annual review of medicine.

[104]  S. Bakos,et al.  Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse , 1999, American Journal of Gastroenterology.

[105]  H. Okamura,et al.  Regulation of interferon-gamma production by IL-12 and IL-18. , 1998, Current opinion in immunology.

[106]  M. McAlindon,et al.  Expression of interleukin 1 â and interleukin 1 â converting enzyme by intestinal macrophages in health and inflammatory bowel disease , 1998 .